Iqvia price target raised to $300 from $260 at Argus

Argus raised the firm’s price target on Iqvia to $300 from $260 and keeps a Buy rating on the shares after its Q4 earnings beat earlier this month. The company delivered strong new order growth and stands to benefit from its sizable backlog and new technology offerings, the analyst tells investors in a research note. Iqvia also operates as a long-cycle business, helping to insulate it from market shocks, the firm added.